Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
Díez, José María
Honrubia, José Manuel
Background: Cross-reactivity against human coronaviruses with Flebogamma® DIF and Gamunex®-C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV). Materials & methods: Neutralization capacity of lots of IVIG manufactured prior to COVID-19 pandemic was assessed against these viruses in cell culture. Infectivity neutralization was quantified by percent reduction in plaque-forming units and/or cytopathic/cytotoxic methods. Results: All IVIG preparations showed neutralization of SARS-CoV-2 isolates. All IVIG lots produced neutralization of SARS-CoV. No IVIG preparation showed significant neutralizing activity against MERS-CoV. Conclusion: The tested IVIG contain antibodies with significant in vitro cross-neutralization capacity against SARS-CoV-2 and SARS-CoV, but not MERS-CoV. These preparations are currently under evaluation as potential therapies for COVID-19.
619 - Veterinary science
Is part of
Díez, José María, Carolina Romero, Júlia Vergara-Alert, Melissa Belló-Perez, Jordi Rodon, José Manuel Honrubia, Joaquim Segalés, Isabel Sola, Luis Enjuanes, and Rodrigo Gajardo. 2020. "Cross-Neutralization Activity Against SARS-Cov-2 Is Present In Currently Available Intravenous Immunoglobulins". Immunotherapy 12 (17): 1247-1255. doi:10.2217/imt-2020-0220.
This item appears in the following Collection(s)
- ARTICLES CIENTÍFICS 
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/